Investor Presentaiton slide image

Investor Presentaiton

R&D investor presentation Icodec, a once-weekly insulin, is designed to raise the innovation-bar through better control and convenience Steady state pharmacodynamic profile of insulin icodec suitable for once-weekly dosing Glucose infusion rate (mg/kg/min) 5 4 3 2 180 0 9 The phase 2 trial compared once-weekly icodec to once-daily insulin glargine Icodec (weekly) + metformin + DPP-4i (+ daily placebo) Insulin glargine U100 (daily) + metformin + DPP-4i (+weekly placebo) Primary endpoint Change in HbA1c from baseline to week 26 Secondary endpoints • Change in FPG, body weight and SMBG Weekly insulin dose during the last two weeks of treatment Hypoglycaemic episodes Icodec 247 people with type 2 diabetes Once-daily insulin treatment 2 4 Time (days) *Steady-state levels of predicted profiles based on modelled phase 1 data. 6 PK: Pharmacokinetics; FPG: Fasting plasma glucose; SMBG: Self monitoring blood glucose Note: Insulin icodec is the international non-proprietary name novo nordisk
View entire presentation